Clinical Trial: Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1

U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07762001) titled 'Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1' on Aug. 06.

Brief Summary: This is a Phase 1 single-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of AD-NP1, a humanized monoclonal antibody targeting human ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1). The study aims to assess the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AD-NP1 in healthy volunteers. Participants will be randomized to receive either AD-NP1 or placebo, with safety and efficacy monitored in accordance with Good Clinical Practice (GCP)...